Targeting hyperproliferative disorders with cyclin dependent kinase inhibitors

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.10, Iss.2, 2000-02, pp. : 215-230

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cyclin-dependent kinase inhibitors closer to market launch?

By Galons Hervé

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 8, 2013-08 ,pp. : 945-963

Informa Healthcare

Access to resources Recommend Favorite

Cyclin-dependent kinase inhibitors: novel anticancer agents

By Mani S. Wang C. Wu K. Francis R. Pestell R.

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 8, 2000-08 ,pp. : 1849-1870

Informa Healthcare

Access to resources Recommend Favorite

Cyclin-Dependent Kinase Inhibitors as Anticancer Drugs

Current Drug Targets, Vol. 11, Iss. 3, 2010-03 ,pp. : 291-302

Bentham Science Publishers

Access to resources Recommend Favorite

Potential Use of Pharmacological Cyclin-Dependent Kinase Inhibitors as Anti-HIV Therapeutics

Current Pharmaceutical Design, Vol. 12, Iss. 16, 2006-06 ,pp. : 1949-1961

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacological Cyclin-Dependent Kinase Inhibitors (PCIs) as Potential Antiviral Drugs

Anti-Infective Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Infective Agents), Vol. 5, Iss. 4, 2006-10 ,pp. : 345-355

Bentham Science Publishers

Access to resources Recommend Favorite